Capital Performance Advisors LLP Royalty Pharma PLC Transaction History
Capital Performance Advisors LLP
- $325 Million
- Q3 2024
A detailed history of Capital Performance Advisors LLP transactions in Royalty Pharma PLC stock. As of the latest transaction made, Capital Performance Advisors LLP holds 43 shares of RPRX stock, worth $1,044. This represents 0.0% of its overall portfolio holdings.
Number of Shares
43Holding current value
$1,044% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding RPRX
# of Institutions
413Shares Held
283MCall Options Held
578KPut Options Held
47.5K-
Morgan Stanley New York, NY41.1MShares$997 Million0.09% of portfolio
-
Vanguard Group Inc Valley Forge, PA37.6MShares$913 Million0.02% of portfolio
-
Black Rock Inc. New York, NY23MShares$559 Million0.01% of portfolio
-
Baillie Gifford & CO16.1MShares$391 Million0.35% of portfolio
-
Viking Global Investors LP12.1MShares$294 Million1.32% of portfolio
About Royalty Pharma plc
- Ticker RPRX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 437,139,008
- Market Cap $10.6B
- Description
- Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic i...